## Abstract ## Objective Although antiphospholipid antibodies (aPL) are associated with arterial and venous thrombosis in systemic lupus erythematosus (SLE), the extent to which they influence other cardiovascular manifestations is either controversial or uncertain. We undertook this study to exam
Relationship of the clinical course of systemic lupus erythematosus to the presence of circulating lymphocytotoxic antibodies
β Scribed by William T. Butler; John T. Sharp; Roger D. Rossen; Martin D. Lidsky; Kamal K. Mittal; Donald A. Gard
- Publisher
- John Wiley and Sons
- Year
- 1972
- Tongue
- English
- Weight
- 467 KB
- Volume
- 15
- Category
- Article
- ISSN
- 0004-3591
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Objective. Characterization of the abundance, origin, and annexin V (AnxV)-binding capabilities of circulating microparticles (MPs) in SLE patients and healthy controls and to determine any associations with clinical parameters. Methods. Seventy unselected SLE patients and 29 sex-and age-matched hea
## Abstract The clinical and renal histologic attributes of 135 systemic lupus erythematosus (SLE) patients with DNA and/or Sm antibodies were compared to determine if the presence of the Sm antibodies served as a marker for a specific subset of SLE. Although Raynaud's phenomenon was more frequent
## Objective: To determine whether antiphospholipid antibodies (apl) occur before the diagnosis of systemic lupus erythematosus (sle) and before initial clotting events, and whether their presence early in the disease course influences clinical outcome. ## Methods: Serum samples obtained from 130